Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revo...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 20, 2024

Statement from the Minister of Indigenous Services on the preliminary findings from the United Nations Special Rapporteur on the • Divert Announces Purchase of New Site in Lexington, North Carolina for Future Integrated Diversion & Energy Facility • T2EARTH Celebrates Earth Day by Leading the Wood Products Industry towards a Sustainable Built Environment • LS Cable & System Welcomes $99 Million Investment Tax Credit Under Section 48C of the Inflation Reduction Act • Strengthening Canadian research and innovation • Engel & Völkers Dallas Fort Worth Presents $20,824 to Special Olympics • Boys & Girls Clubs of the Valley and Ross Stores Celebrated 10-Year Anniversary of "Help Local Kids Thrive" In-Store Fundrai • Coming into Force of Algonquins of Pikwakanagan First Nation's Child and Family Services Law, Nigig Nibi Ki-win • El Car Wash Partners With “CARD” to Support Neurodiversity in the Workplace • Hartford HealthCare makes Earth-friendly pledge of carbon neutrality by 2050 • Island Fin Poké Co. Celebrates Earth Day by Sharing Its Sustainable Efforts Toward a Greener Earth • Prime Minister announces appointment of the next Commissioner of the Northwest Territories • USAA to Gift Vehicles to Military and Their Families in 2024 • T2EARTH Launches Official YouTube Channel – T2EARTH Talks • University of Phoenix College of Nursing Faculty Leadership Selected for Prestigious Fellows of the American Association of Nurs • Energy Transition Accelerator Advances with New Secretariat, Expert Consultative Group • H2 Green Mining and Ohmium Sign Agreement to Boost Green Hydrogen in Chile • Kellanova and Shaw's join No Kid Hungry to help end summer hunger for kids and families in Maine • Clarification of Details Regarding Oceansix's Engagement with RB Milestone Group LLC • Eaton to announce first quarter 2024 earnings on April 30, 2024

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

NEW YORK , June 03 /Businesswire/ - Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230603005001/en/

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research (Photo: Business Wire)

Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services.

Cristina Green, Vice President of Clinical Research, shared her enthusiasm for this partnership, stating, "This collaboration with Massive Bio complements our ability to connect patients with advanced cancer therapies and cutting-edge clinical trials. By leveraging AI-driven precision medicine, we are confident that this partnership will accelerate breakthroughs in cancer research and deliver life-changing treatment options to our patients."

"We are incredibly excited about joining forces with The Oncology Institute," said Selin Kurnaz, Ph.D., CEO of Massive Bio. "This partnership will not only revolutionize cancer care but will also empower patients with access to the most advanced precision medicine available. Our combined expertise will open new doors for patients, connecting them to potentially life-saving treatments and groundbreaking clinical trials."

Furthermore, this collaboration will expand the scope of cancer research through Massive Bio's recent ChatGPT-powered chatbots for oncology research release during ASCO 2023. Dr. Arturo Loaiza-Bonilla, renowned oncologist and a key figure in the development of the chatbot technology, stated, "We are proud to be part of this innovative partnership between Massive Bio and TOI. The integration of AI-driven chatbots with clinical decision-support tools will revolutionize the way researchers access and analyze oncology data, enabling more efficient and impactful research initiatives, and will bolster this newly forged alliance to the betterment of all cancer patients."

The alliance between Massive Bio and TOI represents a paradigm shift in cancer care, combining the power of advanced AI technology, personalized therapy, and an extended network of research collaborations. Together, these industry leaders are poised to reshape the future of oncology and bring new hope to patients and their families.

About Massive Bio:

Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

About TOI

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 700 teammates in over 60 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.